Breast Cancer Research Group Presents Work in San Antonio - Poster 4
Ixabepilone plus capecitabine vs. Capecitabine in patients with metastatic breast cancer receiving ixabepilone in the first line setting: a pooled analysis from two phase III studies.
Vahdat, Fein, Karwal, Campone,Peck, Mukhopadhyay, Jassem
Ixabepilone is a chemotherapy drug with established activity in hard to treat breast cancer. This study looked at its effectiveness is a subgroup of hard to treat relapsed breast cancer: those whose cancer returned within one year of completing adjuvant therapy. What we found was that ixabepilone has a similar efficacy and side effect profile in this hard to treat population as the general population it was tested in.
